GS-441524 is a widely studied antiviral nucleoside analogue commonly associated with feline infectious peritonitis (FIP) management programs. Oral tablet formulations have become a practical choice for veterinarians and pet owners seeking a convenient method of administering antiviral support during extended treatment periods.
Each tablet contains 50mg of GS-441524, providing a higher-potency option that may reduce the number of tablets required per dose. The formulation is designed for oral administration and can be incorporated into weight-based treatment plans developed according to individual feline requirements.
FIP remains one of the most challenging diseases in feline medicine. The condition occurs when feline coronavirus mutates and gains the ability to spread through immune cells, causing inflammation throughout the body. Depending on disease progression, symptoms may involve body cavities, internal organs, the eyes, or the central nervous system.
This product is manufactured under controlled quality standards and packaged to maintain stability throughout storage and transportation.
| Specification | Details |
|---|---|
| Product Name | GS-441524 Tablets |
| Active Component | GS-441524 |
| Strength | 50mg |
| Form | Oral Tablet |
| Intended Use | Cat FIP Support |
| Storage | Room Temperature |
| Shelf Life | 12 Months |
| Origin | China |
Product packaging includes batch numbers and expiration dates for quality control purposes.
Feline infectious peritonitis develops from mutations of feline coronavirus (FCoV). While many cats are exposed to coronavirus during their lifetime, only a small proportion develop FIP.
The disease may appear in different forms:
This presentation commonly involves fluid accumulation around internal organs, particularly in the abdomen or chest.
Dry FIP often affects organs such as the kidneys, liver, lymph nodes, and intestines without significant fluid buildup.
Some cats experience inflammation within the eye, which may affect vision and eye appearance.
Advanced cases may involve the brain and nervous system, resulting in mobility or behavioral changes.
Because the disease manifests differently between patients, treatment plans are usually customized according to veterinary assessment.
Each tablet provides 50mg of GS-441524, making it suitable for treatment plans that require larger daily amounts of antiviral support.
The tablet format eliminates the need for injections and may simplify treatment routines during long-term care.
Veterinary professionals can adjust treatment plans according to the cat’s weight, clinical signs, and response to therapy.
Manufacturing processes are designed to maintain stable active ingredient content and tablet uniformity across production batches.
Room-temperature storage makes the product convenient for transportation, inventory management, and daily use.
GS-441524 tablets are typically administered according to individualized treatment protocols.
| Condition Type | General Consideration |
|---|---|
| Effusive FIP | Standard antiviral management |
| Non-Effusive FIP | Dosage adjustments may be required |
| Ocular Cases | Additional support strategies may be considered |
| Neurological Cases | Higher protocol levels may be recommended |
| Follow-Up Management | Continued observation and dosage review |
Regular veterinary monitoring is recommended throughout treatment.
The 50mg tablet formulation is commonly used in various feline healthcare settings:
Its oral format may help simplify administration during extended treatment cycles.
To preserve tablet quality:
When stored correctly, the product remains stable for up to one year from the manufacturing date.
GS-441524 50mg tablets are packaged for veterinary distribution and feline care programs. Packaging is designed to support product stability during transportation and storage.
Suitable for supply to:
Administration schedules, dosage calculations, and treatment duration should be determined according to veterinary recommendations and the specific condition of the cat.
